Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | RGS12 | O14924 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25334320 | 1.00 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2LMNARGS12NPSR1 | |
| SCHEMBL25335686 | 0.85 | RAB9A (0.69) | ALDH1A1SMN1; SMN2LMNARGS12NPSR1 | |
| SCHEMBL13977439 | 0.84 | RGS12 (0.84) | ALDH1A1SMN1; SMN2LMNARGS12NPSR1 | |
| SCHEMBL4205396 | 0.78 | ALDH1A1 (0.85) | ALDH1A1NPSR1HSD17B10MAPTKDM4E | |
| SCHEMBL25337471 | 0.76 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2LMNAHSD17B10MAPT | |
| SCHEMBL25335765 | 0.75 | ADRB2 (0.76) | ALDH1A1SMN1; SMN2LMNAHSD17B10KDM4E | |
| SCHEMBL15983653 | 0.75 | LMNA (0.66) | ALDH1A1SMN1; SMN2LMNANPSR1HSD17B10 | |
| SCHEMBL4209017 | 0.75 | POLB (0.80) | ALDH1A1LMNAHSD17B10MAPTKDM4E | |
| SCHEMBL2021735 | 0.74 | SMN1; SMN2 (1.00) | ALDH1A1SMN1; SMN2LMNAHSD17B10MAPT | |
| SCHEMBL15983538 | 0.74 | ALDH1A1 (0.77) | ALDH1A1LMNARGS12HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564547-B2 | Compositions, formulations, and methods for skin treatment | ODDITY LABS, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| WO-2023133240-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | REVELA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | CUTA, COL14A1, DSG1 | ALDH1A1 3302/4885SMN1; SMN2 696/4885LMNA 44/4885 |
| US-12564547-B2 | Compositions, formulations, and methods for skin treatment | MCOLN1, H1-0, APOL1 | ALDH1A1 1590/4885SMN1; SMN2 1578/4885LMNA 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.